Our Partners

At EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany in the U.S., we aspire to create, improve and prolong life for people living with difficult-to-treat conditions like infertility, multiple sclerosis and cancer. We have a deep legacy of impacting lives and we’re fueled for the future, driven by patient needs. We’re imagining the future of healthcare by turning science into solutions across a wide range of cancers, multiple sclerosis, and other immunologic disorders.

Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Genentech is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis (MS), spinal muscular atrophy (SMA), neuromyelitis optica spectrum disorder (NMOSD), Alzheimer’s, Huntington’s, Parkinson’s, acute ischemic stroke, Duchenne muscular dystrophy and Angelman syndrome. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

Novartis’ purpose is to reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. We also aim to reward those who invest their money, time and ideas in our company.

We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Since 2012, we’ve been working to improve the lives of people with serious neuro-degenerative diseases. Sanofi is developing new medicines built on patient insights and outstanding science to help the millions of people living with neurological disorders. We engage with the patient advocacy community to listen to their perspectives, understand what matters most to patients, and champion these patient-centric insights internally and externally.

We’re taking on the complex challenges of neurological diseases, advancing scientific understanding and developing treatments to address long-unmet needs. For more than 18 years, we’ve worked relentlessly to deliver disease-modifying therapies for MS with distinct indications and mechanisms of action. The goal is to design best-in-class medicines that slow or halt neurodegeneration, control neuroinflammation, and protect or even repair the nervous system.

Viatris Inc. is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).